Skip to main
TIL
TIL logo

Instil Bio (TIL) Stock Forecast & Price Target

Instil Bio (TIL) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Instil Bio Inc. has positioned itself as a promising player in the biopharmaceutical sector with its innovative approach to cell therapies, particularly through its CoStAR platform, which enhances the efficacy of tumor infiltrating lymphocyte (TIL) therapies against a range of solid tumors. The inclusion of ITIL-306 in its pipeline, targeting tumor-associated antigens relevant to various cancer types, indicates potential for significant therapeutic advances in a market with substantial unmet medical needs. Additionally, positive momentum in related developments within the bispecific therapy landscape, as noted in recent conference updates, may create a favorable environment for TIL therapies, bolstering Instil Bio's growth prospects.

Bears say

Instil Bio Inc. faces significant challenges that contribute to a negative outlook on its stock, primarily driven by concerns over the limited improvement in overall survival (OS) curves observed in clinical updates, which suggests that investor expectations may not be met. Additionally, the company is exposed to risks related to clinical development, including potential delays in advancing its candidates and the inability to produce favorable clinical data for critical therapies such as AXN-2510 in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Furthermore, there is a looming concern regarding medium- to long-term dilution risk, compounded by a stark valuation gap, which raises questions about the company's financial stability and future growth potential.

Instil Bio (TIL) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Instil Bio (TIL) Forecast

Analysts have given Instil Bio (TIL) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Instil Bio (TIL) has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Instil Bio (TIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.